Interested in Monitoring? Call 877-596-2224
Current Customers Call 877-296-6465
Patients & Other Questions Call 877-643-6179
BALTIMORE, MD. – May 5, 2014 — Ameritox, the nation’s leader in medication monitoring solutions, introduced Ingenuity Health, a new service providing highly reliable data and analysis that helps doctors and behavioral health specialists better treat patients diagnosed with serious mental illness.
With Ingenuity Health, Ameritox uses urine drug monitoring to address the knowledge gap around medication adherence for the antipsychotics most frequently prescribed to treat those with serious mental illness (SMI), such as schizophrenia and bipolar disorder. Studies show that approximately half of the more than 7 million U.S. adults diagnosed with SMI don’t take their prescribed medications correctly. The consequences of going untreated are significant both for patients and society and include homelessness, self-inflicted harm and violence toward others, and economic hardship.
A key foundation of this new service is first-of-their-kind tests that enable doctors to compare the results of urine drug monitoring with independent benchmarks to determine more reliably if a patient is taking their medication. In March, Ameritox announced the first of these test results for Abilify, a powerful antipsychotic and the top-selling medication in the U.S. Additional tests are underway for similar medications.
“Knowing whether a patient diagnosed with serious mental illness is taking their medication is an essential part of treatment and prevention of human tragedy,” said Scott Walton, Ameritox chief executive. “With Ingenuity Health, Ameritox is putting the time and resources into providing health-care solutions where they are most needed.”
To determine if patients are taking their medications, behavioral health specialists traditionally have relied on make-do methods like pill counts and patient self-reporting. Blood work is an expensive and invasive option that offers information about a small window of time in a patient’s behavior. Urine drug monitoring offers an easier, less invasive and more accurate approach, especially when combined with independent benchmarks.
“Our data-driven approach can provide clarity in a field that almost exclusively deals with shades of gray,” said Jerry Vaccaro, president of Ingenuity Health. “By eliminating the historical guesswork about whether a patient is taking their prescribed medication, Ingenuity Health aims to free clinicians to focus on helping patients lead full and healthy lives.”
Ameritox helped pioneer the prescription drug monitoring necessary to address the national epidemic of prescription drug misuse, abuse, and diversion. As the nation’s trusted leader in Pain Medication Monitoring SolutionsSM, Ameritox provides medical and business professionals with data-driven analysis and tailored solutions that can improve patient care and prevent tragedy. Ameritox, headquartered in Baltimore, Md., has 800 employees nationwide and laboratory facilities in Greensboro, N.C.
Lon Wagner, Ameritox
Genevieve Rozansky, 30 Point Strategies